sf-837 and Malaria

sf-837 has been researched along with Malaria* in 2 studies

Other Studies

2 other study(ies) available for sf-837 and Malaria

Article	Year
Spectrum of the antimalarial activity of a new macrolide antibiotic midecamycin in mice and monkeys. Chemotherapy, 1989, Volume: 35, Issue:3 The antimalarial activity of a new macrolide antibiotic, midecamycin, has been evaluated against a sensitive strain of Plasmodium berghei, a chloroquine-resistant strain of P. yoelii nigeriensis and a simian parasite, P. cynomolgi B. The ED50 and ED90 values of this antibiotic administered in two divided daily doses were found to be 37.15 +/- 3.51 and 100.84 +/- 7.54 mg/kg, respectively, against P. berghei and 362.34 +/- 85.33 and 878.04 +/- 10.02 mg/kg, respectively, against P. yoelii nigeriensis. Doses above 45 mg/kg for 4 days significantly extended the mean survival time of treated mice infected with either of the two parasites. However, no appreciable blood schizontocidal (at 100 mg/kg X 7 days), anti-relapse (at 100 mg/kg X 7 days) or causal prophylactic activities (at 200 mg/kg X 3 days) were observed against P. cynomolgi infection in rhesus monkeys. Topics: Animals; Antimalarials; Leucomycins; Macaca mulatta; Malaria; Male	1989
[Infectious and parasitic diseases: overview of current status in 1979]. La Revue du praticien, 1979, May-11, Volume: 29, Issue:27 Topics: Anti-Bacterial Agents; Brucellosis; Cephalosporins; Drug Combinations; France; Gentamicins; Hepatitis, Viral, Human; Humans; Legionnaires' Disease; Leucomycins; Malaria; Travel; Tropical Climate; Typhoid Fever; Vaccination	1979

Article

Year

Spectrum of the antimalarial activity of a new macrolide antibiotic midecamycin in mice and monkeys.

Chemotherapy, 1989, Volume: 35, Issue:3

The antimalarial activity of a new macrolide antibiotic, midecamycin, has been evaluated against a sensitive strain of Plasmodium berghei, a chloroquine-resistant strain of P. yoelii nigeriensis and a simian parasite, P. cynomolgi B. The ED50 and ED90 values of this antibiotic administered in two divided daily doses were found to be 37.15 +/- 3.51 and 100.84 +/- 7.54 mg/kg, respectively, against P. berghei and 362.34 +/- 85.33 and 878.04 +/- 10.02 mg/kg, respectively, against P. yoelii nigeriensis. Doses above 45 mg/kg for 4 days significantly extended the mean survival time of treated mice infected with either of the two parasites. However, no appreciable blood schizontocidal (at 100 mg/kg X 7 days), anti-relapse (at 100 mg/kg X 7 days) or causal prophylactic activities (at 200 mg/kg X 3 days) were observed against P. cynomolgi infection in rhesus monkeys.

Topics: Animals; Antimalarials; Leucomycins; Macaca mulatta; Malaria; Male

1989

[Infectious and parasitic diseases: overview of current status in 1979].

La Revue du praticien, 1979, May-11, Volume: 29, Issue:27

Topics: Anti-Bacterial Agents; Brucellosis; Cephalosporins; Drug Combinations; France; Gentamicins; Hepatitis, Viral, Human; Humans; Legionnaires' Disease; Leucomycins; Malaria; Travel; Tropical Climate; Typhoid Fever; Vaccination

1979